# PBS restrictions for T2DM medicines - summary tables

1 April 2025

The following tables provide an abridged description of the revised Pharmaceutical Benefits Scheme (PBS) restrictions for type 2 diabetes mellitus (T2DM) medicines.

**Table 1. PBS Unrestricted medicines and Restricted Benefit medicines for T2DM by class**

|  |  |
| --- | --- |
| **Class** | **Drug** |
| ***Biguanides*** | Metformin |
| ***Sulfonylureas*** | Glibenclamide |
| Gliclazide |
| Glimepiride |
| Glipizide |
| ***Alpha glucosidase inhibitors*** | Acarbose |
| ***Insulins*** | Insulins, except insulin detemir which is a Restricted Benefit for use in type 1 diabetes mellitus |
| ***Thiazolidinediones*** | Pioglitazone |

**Table 2. PBS-subsidised combinations of Authority Required T2DM medicines by drug**

Key: Green = PBS-subsidised, Red = NOT PBS-subsidised, Orange = PBS-subsidised with contraindication/intolerance requirements.

| **Class** | **Drug** **(Brand name)** | **Dual therapy with** **Met or Su** | **Triple therapy with****Met + Su** | **Dual/triple therapy with** **Ins+/- Met** | **Triple therapy with****Met + SGLT2i** | **Triple therapy with****Met + DPP4i** |
| --- | --- | --- | --- | --- | --- | --- |
| DPP4i ‘Gliptins’ | Alogliptin(Nesina®) | 🗸**1** | 🗸 | 🗸 | 🗸 | NA |
| Linagliptin(Trajenta®) | 🗸**1** | 🗸 | 🗸 | 🗸3 | NA |
| Saxagliptin(Onglyza®) | 🗸**1** | 🗸 | 🗸 | 🗸3 | NA |
| Sitagliptin(multiple brands) | 🗸**1** | 🗸 | 🗸 | 🗸3 | NA |
| Vildagliptin(Galvus®) | 🗸**1** | 🗸 | 🗸 | 🗸 | NA |
| SGLT2i‘Flozins’ | Dapagliflozin(Forxiga®) | 🗸2 | 🗸 | 🗸 | NA | 🗸3 |
| Empagliflozin(Jardiance®) | 🗸2 | 🗸 | 🗸 | NA | 🗸3 |
| GLP-1 RAs | Dulaglutide (Trulicity®) | 🗸4 | 🗸4 | 🗸4 | X5 | X |
| Semaglutide (Ozempic®) | 🗸4 | 🗸4 | 🗸4 | X5 | X |

Abbreviations: DPP4i = dipeptidyl peptidase-4 inhibitor, Ins = insulin; Met = metformin, NA = Not applicable; SGLT2i = sodium-glucose cotransporter 2 inhibitor, Su = sulfonylurea.

Quadruple therapy: PBS-subsidised quadruple therapy options have not been included for simplicity. DPP4i and SGLT2i are subsidised for use in combination with each other, insulin and other Unrestricted medicines.

60-day prescriptions: All T2DM medicines, except insulins and GLP-1 RAs, are available for 60-day prescriptions. The patient’s condition must be stable.

Notes:

1. DPP4i with metformin fixed dose combination (FDC) available - not subsidised for initial therapy.
2. SGLT2i with metformin FDC available. SGLT2i are subsidised for initial T2DM therapy without a glycaemic requirement when used in combination with metformin (unless contraindicated/intolerant) for patients with cardiovascular disease, those at high risk of a cardiovascular event, and for Aboriginal or Torres Strait Islander patients.
3. DPP4i with SGLT2i FDC available - not subsidised for initial therapy.
4. Patient must have a contraindication/intolerance requiring treatment discontinuation to an SGLT2 inhibitor, or the patient must not have achieved a clinically meaningful glycaemic response to an SGLT2 inhibitor. Telephone/electronic authority required for initiation.
5. GLP-1 RAs are not subsidised for use in combination with an SGLT2 inhibitor, except where the SGLT2 inhibitor is prescribed for a different indication (e.g., heart failure or kidney disease) and the patient did not achieve a clinically meaningful glycaemic response to the SGLT2 inhibitor.